Evidence map›Paper›PMID 29312259›Full record

ArticleFrontiers in microbiology2017

Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models.

Valerie Defraine, Laure Verstraete, Françoise Van Bambeke, Ahalieyah Anantharajah, Eleanor M Townsend, Gordon Ramage, Romu Corbau, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Bacterial persisters: molecular mechanisms and therapeutic development.Signal transduction and targeted therapy · 2024
    Review
  2. Article
  3. Studying Bacterial Persistence: Established Methods and Current Advances.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Valerie DefraineCentre of Microbial and Plant Genetics, University of Leuven, Leuven, Belgium.
Laure VerstraeteCentre of Microbial and Plant Genetics, University of Leuven, Leuven, Belgium.
Françoise Van BambekePharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Ahalieyah AnantharajahPharmacologie Cellulaire et Moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Eleanor M TownsendOral Science Research Group, Glasgow Dental School, University of Glasgow, Glasgow, United Kingdom.
Gordon RamageOral Science Research Group, Glasgow Dental School, University of Glasgow, Glasgow, United Kingdom.
Romu CorbauCISTIM Leuven vzw, Leuven, Belgium.
Arnaud MarchandCISTIM Leuven vzw, Leuven, Belgium.
Patrick ChaltinCISTIM Leuven vzw, Leuven, Belgium.
Maarten FauvartCentre of Microbial and Plant Genetics, University of Leuven, Leuven, Belgium.
Jan MichielsCentre of Microbial and Plant Genetics, University of Leuven, Leuven, Belgium.
KU Leuven · BEUCLouvain · BEUniversity of Glasgow · GBIMEC · BEVlaams Instituut voor Biotechnologie · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently described the novel anti-persister compound 1-[(2,4-dichlorophenethyl)amino]-3-phenoxypropan-2-ol (SPI009), capable of directly killing persister cells of the Gram-negative pathogen

Indexed as

antibacterialsantibiotic resistanceanti-persister therapiesESKAPE pathogensP. aeruginosa

Identifiers

PMID29312259
PMCPMC5744096
OpenAlexW2781110620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.